The British court judgment may have broad international influence, however, if the European court approves Genentech's patent application, the British court decision can be challenged through accepted European Economic Community (EEC) procedures. 1 The possible litigations do not end here. Integrated Genetics, a Boston-area biotechnology firm, has r-tPA in Phase III clinical trials in Japan. The product is being developed in conjunction with Toyobo and BASP. The company is also in preclinical trials with a proprietary second-generation tPA for which it is currently seeking V.S. and European corporate sponsors.'
This type of patent confusion and legal proceedings may surround the biotechnologic development of other blood proteins, e.g., factor VIII, antithrombin, and serum albumin.
The best donnybrook now running involves erythropoietin (EPO) and recombinant EPO (r-EPO). (Key facts are documented in a Pharmaceutical Executive interview with Gordon Binder, head of Amgen. 3) EPO is produced by the kidney and stimulates production of erythrocytes. Administered to patients with chronic renal failure, it has been shown to be effective in preventing the anemia associated with dialysis. The patent, licensing, and marketing entanglements are complex, but are roughly as follows.
EPO was discovered early this century and reliably isolated from urine in 1977. Amgen researchers cloned and expressed the gene for EPO in 1983 and began human studies in 1985. Amgen filed a product license application (PLA) on October 30, 1987 and updated it in 1988. Meanwhile, Genetics Institute (GI) received in 1987 a patent on a homogenous EPO purified from urine. GI has also developed recombinant DNA technology to produce r-EPO.
GI has now licensed Japan's Chugai to produce a novel form of EPO under the GI patent. Chugai has agreements with Upjohn (V.S.) and Boehringer Ingelheim (Europe) to market the final product. Amgen has entered a marketing arrangement with Ortho, a Johnson and Johnson subsidiary, to market its r-EPO. Ortho has just filed suit against Amgen to delay the product's launch, claiming that Amgen failed to fulfill some terms of their licensing agreement (withholding some potential indications from the marketing agreement). Amgen's PLA was recently approved by the Food and Drug Administration (FDA); the PLA of Upjohn/Chugai is still pending. Meanwhile, Amgen and GI litigation is scheduled to go to trial August 7 in the Boston District Court.
The stakes in this biotech race are considerable. There may be 100 000 patients with renal failure in the U.S. who could be considered candidates for EPO. The drug, administered three times weekly, may cost about $5000 annually for each patient. This half-billion dollar market, although only half that proclaimed for r-tPA prior to its marketing, is great news on Wall Street! Is EPO or r-EPO great news for patients? Yes, particularly with the government and insurance companies paying the bill! Is all well in this litiginous biotechnology battlefield? No! One consequence of the simultaneous development of a product by several companies is the waste of limited, high-quality clinical resources. The money and clinical resources required to ready a product for FDA approval are doubled or tripled. This waste undoubt-edly will be passed to the patient and public. Another problem is that in haste for product approval, only the most obvious clinical questions may be studied. Large, carefully staged trials with important multifactorial design and analysis simply may not be undertaken.
Pharmaceutical corporate identities are becoming increasingly blurred to health professionals. With overnight corporate mergers, comarketing of new products, selling and trading of product rights, and emphasis on acquiring rights to foreign products rather than internal development, corporate respect will prove fleeting to many pharmaceutical and biotechnology companies. Until sane rules and precedents are established on biotechnology patents, the FDA and the industry will be doing a lot of second guessing.
NONPRESCRIPTION DRUG APPROVAL: THERAPEUTIC STRATEGY OR MARKETING DECISION?
Donald C. McLeod THERE ARE BASICALLY two classes of drugs in the U.S., prescription (Rx) and nonprescription (OTC). OTC drugs are not restricted to pharmacies and are available in a wide variety of retail outlets with no professional control or consultation. Insulin is an exception, being OTC but sold only in pharmacies.
Historical Perspective
Most oTC drugs have been designated as such for many years; only a few (i.e., ibuprofen, topical hydrocortisone, diphenhydramine, loperamide) have been recently sponsored by drug companies and approved for OTC use. In one case of Food and Drug Administration (FDA) sponsorship of metaproterenol aerosol, the Pulmonary-Allergy Advisory Committee to the FDA subsequently expressed objection and the FDA reversed its decision and returned metaproterenol to Rx status.
Several drugs are now being "developed" for OTC status by the companies marketing them. These drugs include cimetidine (Smith Kline and French), ranitidine (Glaxo), naproxen (Syntex), sucralfate (Marion) and terfenadine (Merrell Dow). In the case of astemizole (Janssen), this nonsedating antihistamine has been OTC since 1984 in Canada and is now being moved to OTC but pharmacy-only availability in Britain. Meanwhile, its new drug application (NDA) languished for several years at the U.S. FDA, but was recently approved for Rx use.
There are several reasons for company sponsorship of drugs for OTC status. Some drugs have a remarkable safety profile, rather uniform dosing, and are used in common ailments diagnosed by the patient through clear symptoms. OTC status is a method of expanding a market constrained by Rx-only status. Such was the case with topical hydrocortisone and ibuprofen. In the case of cimetidine and ranitidine, each company has drugs in the research pipeline that can replace these agents as Rx drugs and which will have extended patent protection. If physician prescribing habits are converted to the new agents, market share will be increased as cimetidine and ranitidine gain OTC market share from current antacid sales. Thus, generic Rx competition may be lessened and overall market share increased. OTC products typically are licensed to firms with strong consumer marketing power so as not to impede an otherwise efficient Rx sales effort to physicians, hospitals, and managed health care systems. A driving force in the Rx-to-OTC movement may be the looming approval of a new drug class in a therapeutic
